Palivizumab

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: January 16, 2026

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab.

Journal: The Pediatric infectious disease journal

Published: January 06, 2026

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: December 02, 2025

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants.

Journal: Cureus

Published: November 22, 2025

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Journal: Expert review of vaccines

Published: November 18, 2025

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: November 14, 2025

Updated Swedish guidelines for the management and treatment of RSV infection.

Journal: Infectious diseases (London, England)

Published: November 08, 2025

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.

Journal: Cureus

Published: October 13, 2025

Respiratory syncytial virus. What's new in prevention?

Journal: Seminars in fetal & neonatal medicine

Published: October 08, 2025

Subgroup limitations and imaging variability in palivizumab studies: implications for public health assessment.

Journal: European journal of pediatrics

Published: September 29, 2025

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

Journal: mAbs

Published: September 25, 2025

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.

Journal: International journal of technology assessment in health care

Published: September 22, 2025

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab.

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab.

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants.

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants.

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Updated Swedish guidelines for the management and treatment of RSV infection.

Updated Swedish guidelines for the management and treatment of RSV infection.

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.

Respiratory syncytial virus. What's new in prevention?

Respiratory syncytial virus. What's new in prevention?

Subgroup limitations and imaging variability in palivizumab studies: implications for public health assessment.

Subgroup limitations and imaging variability in palivizumab studies: implications for public health assessment.

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.